Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study
Objectives: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England. Methods: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode S...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224000377 |
| _version_ | 1797209672603664384 |
|---|---|
| author | Subrata Ghosh Ana Antunes Hanna Rinta-Kokko Elena Chaparova Sarah Lay-Flurrie Aurore Tricotel Fredrik L. Andersson |
| author_facet | Subrata Ghosh Ana Antunes Hanna Rinta-Kokko Elena Chaparova Sarah Lay-Flurrie Aurore Tricotel Fredrik L. Andersson |
| author_sort | Subrata Ghosh |
| collection | DOAJ |
| description | Objectives: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England. Methods: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode Statistics. Patients diagnosed with CDI in hospital and community settings during 2015-2018 were included and followed for ≥1 year. All-cause mortality was described at 6, 12, and 24 months. Healthcare resource usage (HCRU) and associated costs were assessed at 12 months of follow-up. A cohort of non-CDI patients, matched by demographic and clinical characteristics including Charlson Comorbidity Index score, was used to assess excess mortality and incremental costs of HCRU. Results: All-cause mortality among CDI patients at 6, 12, and 24 months was 15.87%, 20.37%, and 27.03%, respectively. A higher proportion of rCDI patients died at any point during follow-up. Compared with matched non-CDI patients, excess mortality was highest at 6 months with 1.81 and 2.53 deaths per 100 patient-months among CDI and ≥1 rCDI patients. Hospitalizations were the main drivers of costs, with an incremental cost of £1209.21 per CDI patient. HCRU and costs increased with rCDIs. Conclusion: CDI poses a substantial mortality and economic burden, further amplified by rCDIs. |
| first_indexed | 2024-04-24T09:58:25Z |
| format | Article |
| id | doaj.art-2ace7aa3470a46ab843168461d4af5f2 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-24T09:58:25Z |
| publishDate | 2024-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-2ace7aa3470a46ab843168461d4af5f22024-04-14T04:10:10ZengElsevierInternational Journal of Infectious Diseases1201-97122024-05-01142106967Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England studySubrata Ghosh0Ana Antunes1Hanna Rinta-Kokko2Elena Chaparova3Sarah Lay-Flurrie4Aurore Tricotel5Fredrik L. Andersson6College of Medicine and Health, University College Cork, Cork, Ireland; University of Birmingham, Birmingham, United KingdomIQVIA, Global Database Studies, Real World Solutions, Lisbon, Portugal; Corresponding author: Ana Antunes, IQVIA, Lagoas Park, Edifício 3, Oeiras, Lisbon, 2740-266, Portugal.IQVIA, Global Database Studies, Real World Solutions, Espoo, FinlandIQVIA, Real World Solutions, Sofia, BulgariaIQVIA, Real World Solutions, London, United KingdomIQVIA, Real World Solutions, Paris, FranceFerring Pharmaceuticals, Copenhagen, DenmarkObjectives: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England. Methods: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode Statistics. Patients diagnosed with CDI in hospital and community settings during 2015-2018 were included and followed for ≥1 year. All-cause mortality was described at 6, 12, and 24 months. Healthcare resource usage (HCRU) and associated costs were assessed at 12 months of follow-up. A cohort of non-CDI patients, matched by demographic and clinical characteristics including Charlson Comorbidity Index score, was used to assess excess mortality and incremental costs of HCRU. Results: All-cause mortality among CDI patients at 6, 12, and 24 months was 15.87%, 20.37%, and 27.03%, respectively. A higher proportion of rCDI patients died at any point during follow-up. Compared with matched non-CDI patients, excess mortality was highest at 6 months with 1.81 and 2.53 deaths per 100 patient-months among CDI and ≥1 rCDI patients. Hospitalizations were the main drivers of costs, with an incremental cost of £1209.21 per CDI patient. HCRU and costs increased with rCDIs. Conclusion: CDI poses a substantial mortality and economic burden, further amplified by rCDIs.http://www.sciencedirect.com/science/article/pii/S1201971224000377Clostridioides difficileRecurrenceMortalityHealthcare costsEnglandRECUR |
| spellingShingle | Subrata Ghosh Ana Antunes Hanna Rinta-Kokko Elena Chaparova Sarah Lay-Flurrie Aurore Tricotel Fredrik L. Andersson Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study International Journal of Infectious Diseases Clostridioides difficile Recurrence Mortality Healthcare costs England RECUR |
| title | Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study |
| title_full | Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study |
| title_fullStr | Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study |
| title_full_unstemmed | Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study |
| title_short | Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study |
| title_sort | estimating excess mortality and economic burden of clostridioides difficile infections and recurrences during 2015 2019 the recur england study |
| topic | Clostridioides difficile Recurrence Mortality Healthcare costs England RECUR |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224000377 |
| work_keys_str_mv | AT subrataghosh estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy AT anaantunes estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy AT hannarintakokko estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy AT elenachaparova estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy AT sarahlayflurrie estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy AT auroretricotel estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy AT fredriklandersson estimatingexcessmortalityandeconomicburdenofclostridioidesdifficileinfectionsandrecurrencesduring20152019therecurenglandstudy |